Oncology Care

Brand Name: Hertraz^TM
Generic name: Trastuzumab for Injection (r-DNA origin)
SKU: 150 mg/440 mg
How supplied: Vial
Storage Conditions (As per PI): Hertraz™ vials are stable at 2−8°C prior to reconstitution. Do not use beyond the expiration date stamped on the vial. Hertraz™150 & 440mg (multi -dose vials) reconstituted with the supplied BWFI is stable for 28 days when stored at 2−8°C. Do not freeze the reconstituted solution
Abbreviated prescribed information:
Hertraz™150 mg & 440 mg multi-dose vials contain lyophilized powder for concentrate for solution for intravenous infusion. Hertraz™150 mg is reconstituted with 7.2 ml bacteriostatic water for injection (BWFI) and Hertraz™440 mg should be reconstituted with 20 ml of BWFI. Reconstituted Hertraz™ concentrate contains approximately 21 mg/ml of Trastuzumab. Calculate the volume of the 21 mg/ml reconstituted Hertraz™ solution
needed, withdraw this amount from the vial and add it to an infusion bag containing 250 ml of 0.9% Sodium Chloride Injection, USP. Do not use Dextrose (5%) solution.
Indications:
Metastatic Breast Cancer (MBC) Hertraz™ is indicated for the treatment of metastatic breast cancer patients who have human epidermal growth factor receptor 2- (HER2)-overexpressing tumours.
Early Breast Cancer (EBC) Hertraz™ is indicated for the treatment of adult patients with HER2 positive early breast cancer.
Metastatic Gastric Cancer (MGC) Hertraz™ in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
DOSAGE & ADMINISTRATION:
Hertraz™ should be administered as intravenous infusion and not as an intravenous push or bolus. For HER2 positive breast cancer administer at either: initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly after beginning one week of initial dose, or Initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30 minutes IV infusion every three weeks after beginning three weeks of initial dose. For Metastatic gastric cancer (MGC) administer Initial dose of 8 mg/kg, then 6 mg/kg every three weeks after beginning three weeks of initial dose.

Disclaimer:  For more details refer to full prescribing information leaflet.

Brand Name: Abevmy^®
Generic name: Bevacizumab for Injection
SKU: 100 mg/ 440 mg
How supplied: Vial
Storage Conditions (As per PI): Store vials at 2°C–8°C. Keep out of reach of children. Keep vial in the outer carton in order to protect from light.
Abbreviated prescribed information:
Each Abevmy^® 100 mg in 4 ml vial contains 100 mg and each Abevmy^® 400 mg in 16 ml vial contains 400 mg of bevacizumab concentrate for solution for IV infusion.
Indications:
Metastatic carcinoma of the colon or rectum: Treatment of adult patients with metastatic carcinoma of the colon or rectum in combination with fluoropyrimidine-based chemotherapy.
Non-squamous Non-small Cell Lung Cancer (NSCLC): First-line treatment of non-squamous NSCLC in combination with platinum-based chemotherapy and for first-line treatment of non-squamous NSCLC with EGFR activating mutations in combination with erlotinib.
Glioblastoma: As a single agent for adult patients with progressive disease following prior therapy.
Advanced and/or metastatic renal cell cancer (mRCC): First-line treatment in combination with interferon alpha-2a of adult patients with advanced and/or metastatic renal cell cancer. Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Front-line treatment in combination with carboplatin and paclitaxel of adult patients. Treatment in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by use as a single agent for adult patients with platinum-sensitive recurrent cancer who have not received prior therapy with bevacizumab, other VEGF inhibitors, or VEGF receptor–targeted agents. Treatment in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin of adult patients with platinum-resistant recurrent cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab, other VEGF inhibitors, or VEGF receptor–targeted agents.
Metastatic carcinoma of the cervix: Treatment of persistent, recurrent, or metastatic carcinoma of the cervix in adult patients, in combination with paclitaxel and cisplatin; or, alternatively, paclitaxel and topotecan for those who cannot receive platinum therapy.
Dosage and Administration: Deliver the initial bevacizumab dose as an IV infusion, over 90 minutes. The second infusion can be administered over 60 minutes, if the first is well tolerated; and subsequent infusions can be administered over 30 minutes, if infusion over 60 minutes is tolerated.
Metastatic Colorectal Cancer (mCRC): The recommended dose of bevacizumab, administered as an IV, is either 5 mg/kg or 10 mg/kg of body weight given
once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks.
NSCLC: 15 mg/kg of body weight given once every 3 weeks.
Glioblastoma: 10 mg/kg of body weight given once every 2 weeks or 7.5 mg/kg or 15 mg/kg of body weight given once every 3 weeks.
mRCC: 10 mg/kg of body weight given as an IV infusion once every 2 weeks, in combination with interferon alpha.
Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: Front line: 15 mg/kg of body weight given once every 3 weeks up to six cycles of treatment; thereafter, continue bevacizumab as a single agent for 15 months or until disease progression, whichever occurs earlier. For recurrent ovarian cancer 15 mg/kg of bodyweight given once every 3 weeks. Metastatic carcinoma of the cervix: 15 mg/kg of body weight given once every 3 weeks. For majority of the indications, continue bevacizumab treatment until progression of the underlying disease or unacceptable toxicity.

Disclaimer:  For more details refer to full prescribing information leaflet.